AU703152B2 - Humanized antibodies against leukocyte adhesion molecule VLA-4 - Google Patents

Humanized antibodies against leukocyte adhesion molecule VLA-4 Download PDF

Info

Publication number
AU703152B2
AU703152B2 AU16960/95A AU1696095A AU703152B2 AU 703152 B2 AU703152 B2 AU 703152B2 AU 16960/95 A AU16960/95 A AU 16960/95A AU 1696095 A AU1696095 A AU 1696095A AU 703152 B2 AU703152 B2 AU 703152B2
Authority
AU
Australia
Prior art keywords
humanized
ser
immunoglobulin
mouse
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU16960/95A
Other languages
English (en)
Other versions
AU1696095A (en
Inventor
Mary M Bendig
Tarran S Jones
Olivier J Leger
Jose Saldanha
Ted A. Yednock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Athena Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc filed Critical Athena Neurosciences Inc
Publication of AU1696095A publication Critical patent/AU1696095A/en
Application granted granted Critical
Publication of AU703152B2 publication Critical patent/AU703152B2/en
Assigned to ELAN PHARMACEUTICALS, INC. reassignment ELAN PHARMACEUTICALS, INC. Alteration of Name(s) in Register under S187 Assignors: ATHENA NEUROSCIENCES, INC.
Assigned to BIOGEN IDEC MA INC. reassignment BIOGEN IDEC MA INC. Alteration of Name(s) in Register under S187 Assignors: ELAN PHARMACEUTICALS, INC.
Assigned to BIOGEN MA INC. reassignment BIOGEN MA INC. Request to Amend Deed and Register Assignors: BIOGEN IDEC MA INC.
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU16960/95A 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule VLA-4 Expired AU703152B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
US08/186269 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (2)

Publication Number Publication Date
AU1696095A AU1696095A (en) 1995-08-08
AU703152B2 true AU703152B2 (en) 1999-03-18

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16960/95A Expired AU703152B2 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule VLA-4

Country Status (21)

Country Link
EP (2) EP0804237B8 (cg-RX-API-DMAC7.html)
JP (5) JP4115517B2 (cg-RX-API-DMAC7.html)
KR (1) KR100367948B1 (cg-RX-API-DMAC7.html)
CN (1) CN1211123C (cg-RX-API-DMAC7.html)
AT (1) ATE333895T1 (cg-RX-API-DMAC7.html)
AU (1) AU703152B2 (cg-RX-API-DMAC7.html)
CA (1) CA2182013C (cg-RX-API-DMAC7.html)
DE (2) DE122006000043I1 (cg-RX-API-DMAC7.html)
DK (2) DK0804237T3 (cg-RX-API-DMAC7.html)
ES (2) ES2270425T3 (cg-RX-API-DMAC7.html)
FI (1) FI117509B (cg-RX-API-DMAC7.html)
FR (1) FR06C0024I2 (cg-RX-API-DMAC7.html)
HU (1) HU220799B1 (cg-RX-API-DMAC7.html)
LU (1) LU91271I2 (cg-RX-API-DMAC7.html)
MX (1) MX9602971A (cg-RX-API-DMAC7.html)
NL (1) NL300238I2 (cg-RX-API-DMAC7.html)
NO (3) NO319867B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ279730A (cg-RX-API-DMAC7.html)
PL (1) PL181827B1 (cg-RX-API-DMAC7.html)
PT (1) PT804237E (cg-RX-API-DMAC7.html)
WO (1) WO1995019790A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
ATE161730T1 (de) * 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU7348798A (en) * 1997-05-09 1998-12-08 John P. Robarts Research Institute, The Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP2065050A1 (en) * 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CA2370814C (en) 1999-04-22 2010-07-06 Biogen, Inc. Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ300710B6 (cs) 1999-06-01 2009-07-22 Biogen Idec Ma Inc. Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2140881B1 (en) * 1999-12-16 2013-04-17 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Vla-1에 대한 항체들
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
US20040009169A1 (en) * 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
MXPA05006384A (es) * 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
EP1827491A4 (en) * 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
US20070122404A1 (en) * 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AR067011A1 (es) * 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
EP2221325B1 (en) 2007-12-13 2014-04-16 Tokuyama Corporation Photochromic curable composition
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
MX338969B (es) 2009-03-20 2016-05-06 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20140161794A1 (en) 2010-04-16 2014-06-12 Biogen Idec Ma Inc. Anti-vla-4 antibodies
ES2646717T3 (es) 2011-05-02 2017-12-15 Millennium Pharmaceuticals, Inc. Formulación para anticuerpo anti- 4 7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
WO2018091729A2 (en) 2016-11-21 2018-05-24 Zaklady Farmaceutyczne Polpharma Sa Aqueous pharmaceutical formulations
CN110997714B (zh) * 2017-02-17 2024-05-03 赛诺菲 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
EP4284947A1 (en) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003252A1 (en) * 1989-09-01 1991-03-21 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2129637C (en) * 1992-02-12 1999-05-04 Roy R. Lobb Treatment for inflammatory bowel disease
ATE182625T1 (de) * 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003252A1 (en) * 1989-09-01 1991-03-21 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGENT ACTIONS 39(1993) 77-9 *
NATURE (1992) 356, 63-6 *

Also Published As

Publication number Publication date
NO2017040I2 (no) 2018-08-28
NZ279730A (en) 1998-04-27
CN1211123C (zh) 2005-07-20
EP1759709B1 (en) 2013-02-27
DE122006000043I1 (de) 2007-02-15
NO2006008I1 (no) 2006-08-07
NO2006008I2 (no) 2009-06-15
EP1759709A1 (en) 2007-03-07
DE69535133D1 (de) 2006-09-07
FI117509B (fi) 2006-11-15
HU9602019D0 (en) 1996-09-30
MX9602971A (es) 1998-01-31
FI962958L (fi) 1996-09-24
JP5487382B2 (ja) 2014-05-07
NL300238I1 (cg-RX-API-DMAC7.html) 2006-10-02
EP0804237B1 (en) 2006-07-26
EP0804237B8 (en) 2006-11-08
AU1696095A (en) 1995-08-08
KR100367948B1 (ko) 2003-07-12
CN1140413A (zh) 1997-01-15
EP0804237A1 (en) 1997-11-05
KR970700513A (ko) 1997-02-12
JPH09508272A (ja) 1997-08-26
EP0804237A4 (en) 2003-04-16
ATE333895T1 (de) 2006-08-15
JP2013165718A (ja) 2013-08-29
HU220799B1 (hu) 2002-05-28
NO319867B1 (no) 2005-09-26
DE69535133T2 (de) 2008-08-21
NO963097L (no) 1996-09-24
LU91271I2 (fr) 2006-10-02
FR06C0024I2 (fr) 2009-01-02
JP2009235078A (ja) 2009-10-15
ES2270425T3 (es) 2007-04-01
HUT75129A (en) 1997-04-28
PL315634A1 (en) 1996-11-25
PT804237E (pt) 2006-10-31
ES2424292T3 (es) 2013-09-30
JP2013173738A (ja) 2013-09-05
JP4115517B2 (ja) 2008-07-09
FR06C0024I1 (cg-RX-API-DMAC7.html) 2006-10-13
NL300238I2 (nl) 2007-05-01
WO1995019790A1 (en) 1995-07-27
DK0804237T3 (da) 2006-10-16
NO963097D0 (no) 1996-07-24
FI962958A0 (fi) 1996-07-24
JP2006045237A (ja) 2006-02-16
NO2017040I1 (no) 2017-08-01
DK1759709T3 (da) 2013-06-10
CA2182013C (en) 2007-07-17
CA2182013A1 (en) 1995-07-27
PL181827B1 (pl) 2001-09-28

Similar Documents

Publication Publication Date Title
AU703152B2 (en) Humanized antibodies against leukocyte adhesion molecule VLA-4
US5840299A (en) Humanized antibodies against leukocyte adhesion molecule VLA-4
US8246958B2 (en) Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
CA2153692C (en) Recombinant anti-vla4 antibody molecules
AU747898B2 (en) Monoclonal antibodies to human CD6
EP0856009A1 (en) Cd6 ligand
WO2007007152A2 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma
WO2007007160A2 (en) Anti-madcam antibodies to treat fever
EP1904103A2 (en) Use of anti-madcam antibodies for the treatment of coeliac disease and tropical sprue
JP2000014383A (ja) ヒト化抗体
HK1011031B (en) Recombinant anti-vla4 antibody molecules

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTORS TO INCLUDE TED A YEDNOCK

PC Assignment registered

Owner name: ELAN PHARMACEUTICALS

Free format text: FORMER OWNER WAS: ATHENA NEUROSCIENCES, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired